Leman Biotech is a clinical-stage cancer immunotherapy company co-founded by the team led by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and AI-driven drug R&D leader XtalPi. The company combines innovative metabolic reprogramming technology with a cutting-edge AI drug discovery platform to develop next-generation cancer immunotherapies. Our Meta 10 core technology, has the potential to cure solid tumors and has been published in the top academic journal, Nature Immunology. Furthermore, it has PCT patents in 56 countries and regions, covering major economies in the world. Leman Biotech has a highly qualified R&D team, with over 70% of its personnel graduating from esteemed Chinese and international universities and possessing extensive industrial experience. In December 2021, only six months after its inception, Leman Biotech completed a successful angel round of financing, raising nearly $11 million, with plans for further financing underway.

Leman Biotech is committed to finding solutions to the bottlenecks in cancer immunotherapy, improving the response rate and efficacy, and making unremitting efforts to achieve the ultimate goal of curing cancer. The company has several R&D pipelines in advanced stages of development, including a metabolically armed CAR-T cell therapy currently in IIT clinical research stage.